Steven L. Warner

3.2k total citations
76 papers, 1.5k citations indexed

About

Steven L. Warner is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Steven L. Warner has authored 76 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 30 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Steven L. Warner's work include Phagocytosis and Immune Regulation (23 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Steven L. Warner is often cited by papers focused on Phagocytosis and Immune Regulation (23 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Steven L. Warner collaborates with scholars based in United States, China and Japan. Steven L. Warner's co-authors include David J. Bearss, Hariprasad Vankayalapati, Sunil Sharma, Daniel D. Von Hoff, Haiyong Han, Anupam Verma, Bret J. Stephens, Venkataswamy Sorna, Emily R. Theisen and Clifford J. Whatcott and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Development.

In The Last Decade

Steven L. Warner

73 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven L. Warner United States 20 810 425 337 218 164 76 1.5k
Rebecca Marnocha United States 17 726 0.9× 476 1.1× 208 0.6× 71 0.3× 84 0.5× 35 1.3k
Wilberto Nieves‐Neira United States 17 1.2k 1.5× 671 1.6× 138 0.4× 146 0.7× 58 0.4× 29 1.7k
Haluk Yuzugullu France 10 1.4k 1.7× 541 1.3× 154 0.5× 116 0.5× 117 0.7× 12 1.8k
Yuning Liao China 25 1.1k 1.4× 455 1.1× 108 0.3× 179 0.8× 70 0.4× 58 1.6k
Audrey Sirvent France 20 808 1.0× 939 2.2× 152 0.5× 155 0.7× 114 0.7× 32 1.8k
Hudie Wei China 14 835 1.0× 550 1.3× 211 0.6× 53 0.2× 69 0.4× 31 1.5k
Jingshan Tong United States 20 906 1.1× 410 1.0× 171 0.5× 174 0.8× 60 0.4× 32 1.3k
Robert Wieder United States 25 907 1.1× 569 1.3× 112 0.3× 210 1.0× 81 0.5× 66 1.6k
Matthew Squires United States 25 1.1k 1.4× 825 1.9× 137 0.4× 262 1.2× 220 1.3× 71 1.9k
Sally Przybranowski United States 16 1.8k 2.2× 757 1.8× 278 0.8× 119 0.5× 267 1.6× 24 2.5k

Countries citing papers authored by Steven L. Warner

Since Specialization
Citations

This map shows the geographic impact of Steven L. Warner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven L. Warner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven L. Warner more than expected).

Fields of papers citing papers by Steven L. Warner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven L. Warner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven L. Warner. The network helps show where Steven L. Warner may publish in the future.

Co-authorship network of co-authors of Steven L. Warner

This figure shows the co-authorship network connecting the top 25 collaborators of Steven L. Warner. A scholar is included among the top collaborators of Steven L. Warner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven L. Warner. Steven L. Warner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fiskus, Warren, Christopher P. Mill, Christine Birdwell, et al.. (2025). Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models. Blood. 146(Supplement 1). 1497–1497.
2.
Jaggupilli, Appalaraju, Bin Yuan, Venkatesh L. Hegde, et al.. (2023). TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. 38(1). 82–95. 1 indexed citations
3.
Heinz, Richard E., Yuta Matsumura, David A. Kircher, et al.. (2023). Abstract 1617: TGFBR1 as a novel therapeutic target in adult granulosa cell tumors. Cancer Research. 83(7_Supplement). 1617–1617. 1 indexed citations
4.
Arner, Emily N., Ali A. Rizvi, Jason E. Toombs, et al.. (2021). AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer. Molecular Cancer Therapeutics. 21(1). 38–47. 22 indexed citations
5.
Yang, Yue, Bao T. Le, Zhenjia Wang, et al.. (2021). Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. Leukemia. 36(3). 746–759. 22 indexed citations
6.
Matsumura, Yuta, Ethika Tyagi, Jason M. Foulks, et al.. (2019). Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models. Molecular Cancer Therapeutics. 18(12_Supplement). C081–C081. 1 indexed citations
7.
Zheng, Qiang, Steven L. Warner, Gregory E. Tasian, & Yong Fan. (2018). A Dynamic Graph Cuts Method with Integrated Multiple Feature Maps for Segmenting Kidneys in 2D Ultrasound Images. Academic Radiology. 25(9). 1136–1145. 33 indexed citations
8.
Park, Il‐Kyoo, Daelynn R. Buelow, Clifford J. Whatcott, et al.. (2017). TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition. Blood. 130. 2522–2522. 1 indexed citations
9.
Chen, Ting, Venkataswamy Sorna, Jared Bearss, et al.. (2017). Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(24). 5473–5480. 13 indexed citations
10.
Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2015). Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical Cancer Research. 21(9). 2115–2126. 59 indexed citations
11.
12.
Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2014). Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors. Blood. 124(21). 1946–1946. 2 indexed citations
13.
Wang, Xiaoping, Hitomi Saso, Takayuki Iwamoto, et al.. (2013). TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research. 73(21). 6516–6525. 65 indexed citations
14.
Ahmed, Kausar Begam Riaz, Steven L. Warner, Andrew Chen, et al.. (2010). In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Experimental Hematology. 39(1). 14–25. 5 indexed citations
15.
Davis, John A., et al.. (2010). Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Experimental Cell Research. 317(3). 307–318. 5 indexed citations
16.
Warner, Steven L., Bret J. Stephens, Galen Hostetter, et al.. (2009). Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. Clinical Cancer Research. 15(21). 6519–6528. 86 indexed citations
17.
Liu, Xiaohui, et al.. (2009). Targeting Axl Kinase in Hematological Malignancies.. Blood. 114(22). 2758–2758. 1 indexed citations
18.
Warner, Steven L., Bret J. Stephens, & Daniel D. Von Hoff. (2008). Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Current Oncology Reports. 10(2). 122–129. 21 indexed citations
19.
Grand, Cory L., et al.. (2007). MP470 suppresses repair of double-strand breaks following treatment with DNA-damaging agents.. Molecular Cancer Therapeutics. 6. 2 indexed citations
20.
Liu, Xiaohui, et al.. (2007). A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies. Molecular Cancer Therapeutics. 6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Marnocha Breakdown of academic impact, for papers by Wilberto Nieves‐Neira Breakdown of academic impact, for papers by Haluk Yuzugullu Breakdown of academic impact, for papers by Yuning Liao Breakdown of academic impact, for papers by Audrey Sirvent Breakdown of academic impact, for papers by Hudie Wei Breakdown of academic impact, for papers by Jingshan Tong Breakdown of academic impact, for papers by Robert Wieder Breakdown of academic impact, for papers by Matthew Squires Breakdown of academic impact, for papers by Sally Przybranowski
Rankless by CCL
2026